121. The global impact of the COVID-19 pandemic on the management and course of chronic urticariaEmek Kocatürk, Andaç Salman, Ivan Cherrez-Ojeda, Paulo Ricardo Criado, Jonny Peter, Elif Comert-Ozer, Mohamed Abuzakouk, Rosana Câmara Agondi, Mona Al-Ahmad, Sabine Altrichter, Mojca Bizjak, Mitja Košnik, 2020, izvirni znanstveni članek Povzetek: Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
Ključne besede: chronic urticaria, pandemics, omalizumab, cyclosporine, COVID-19, SARS-CoV-2, UCARE, treatment
Objavljeno v DiRROS: 14.12.2020; Ogledov: 1472; Prenosov: 368
 Povezava na datoteko |
122. Cold urticaria : what we know and what we do not knowNatalya Maltseva, Elena Borzova, Daria Fomina, Mojca Bizjak, Dorothea Terhorst, Mitja Košnik, Kanokvalai Kulthanan, Raisa Meshkova, Simon Francis Thomsen, Marcus Maurer, 2020, izvirni znanstveni članek Povzetek: Cold urticaria (ColdU) is a common form of chronic inducible urticaria characterised by the development of wheals, angioedema or both in response to cold exposure. Recent research and guideline updates have advanced our understanding and management of ColdU. Today, its pathophysiology is thought to involve the cold-induced formation of autoallergens and IgE to these autoallergens, which provoke a release of proinflammatory mediators from skin mast cells. The classification of ColdU includes typical and atypical subtypes. We know that cold-induced wheals usually develop on rewarming and resolve within an hour and that anaphylaxis can occur. The diagnosis relies on the patient's history and cold stimulation testing. Additional diagnostic work-up, including a search for underlying infections, should only be done if indicated by the patient's history. The management of ColdU includes cold avoidance, the regular use of nonsedating antihistamines, and the off-label use of omalizumab. However, many questions regarding ColdU remain unanswered. Here, we review what is known about ColdU, and we present important unanswered questions on the epidemiology, underlying pathomechanisms, clinical heterogeneity and treatment outcomes. Our aim is to guide future efforts that will close these knowledge gaps and advance the management of ColdU.
Ključne besede: urticaria, cryopyrin-associated periodic syndromes, cold-induced urticaria, familial cold autoinflammatory syndrome, cold stimulation testing, wheals, cryoglobulinemic vasculitis, cryoglobulins
Objavljeno v DiRROS: 14.12.2020; Ogledov: 1319; Prenosov: 374
Povezava na datoteko |
123. Hereditary angioedema due to C1-inhibitor deficiency in Macedonia : clinical characteristics, novel SERPING1 mutations, and genetic factors modifying the clinical phenotypeVesna Grivčeva-Panovska, Mitja Košnik, Peter Korošec, Slađana Andrejević, Ljerka Karadža-Lapić, Matija Rijavec, 2018, izvirni znanstveni članek Povzetek: Objective: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare disease, characterized by swellings. We aimed to characterize on a clinical and molecular basis C1-INH-HAE patients in the Republic of Macedonia. Results: All 15 patients from six unrelated families were diagnosed with C1-INHHAE type I, with a mean age of symptom onset of 11 years and an average delay of diagnosis of 7 years. Patients reported on average 31 angioedema attacks/year, with a median clinical severity score (CSS) of 7. We identified three known mutations, and two mutations (c.813_818delCAACAA and c.1488T>G) were reported for the first time. To address the genotype-phenotype association, a pooled analysis including 78 C1-INH-HAE south-eastern European patients was performed, with additional analysis of F12-46C/T and KLKB1- 428G/A polymorphisms. We demonstrated that patients with nonsense and frameshift mutations, large deletions/insertions, splicing defects, and mutations at Arg444 exhibited an increased CSS compared with missense mutations, excluding mutations at Arg444. In addition, the CC F12-46C/T polymorphism was suggestive of earlier disease onset. Discussion: Genetic analysis helped identify the molecular basis of C1-INH-HAE given that causative mutations in SERPING1 were detected in all patients, including an infant before the appearance of clinical symptoms. We identified two novel mutations and further corroborated the genotype-phenotype relationship, wherein mutations with a clear effect on C1-INH function predispose patients to a more severe disease phenotype and CC F12-46C/T predisposes patients to earlier disease onset.
Ključne besede: hereditary angioedemas -- genetics -- Macedonia, C1 inhibitor, SERPING1 gene, C1 inhibitor, SERPING1 gene
Objavljeno v DiRROS: 30.11.2020; Ogledov: 1297; Prenosov: 284
Povezava na datoteko |
124. Razmejitev provenienčnih območij gozdnih drevesnih vrst v Sloveniji na osnovi ekoloških regijLado Kutnar, Mitja Zupančič, Dušan Robič, Nina Zupančič, Sašo Žitnik, Tone Kralj, Irena Tavčar, Mojca Dolinar, Ciril Zrnec, Hojka Kraigher, 2002, strokovni članek Povzetek: Zakon o gozdnem reprodukcijskem materialu, ki je bil sprejet junija 2002, v skladu z Direktivo EU o gozdnem reprodukcijskem materialu, zahteva določitev provenienčnih območij za pridobivanje in uporabo gozdnega reprodukcijskega materiala. V prispevku je predstavljen predlog oblikovanja ekoloških regij in podregij, ki so osnova za predlagano razmejitev provenienčnih območij. Meje ekoloških regij so lahko prehodne ali mozaično razporejene. Zaradi lažjega določanja provenienčnih območij na terenu in lažjega nadzora nad sadnjo oziroma setvijo so meje provenienčnih območij čimbolj prilagojene gospodarsko-ureditvenim in administrativnim mejam, ki so po možnosti označene na terenu. Predstavljene so osnove za oblikovanje in predlog razmejitve 7 provenienčnih območij, razdeljenih na štiri višinske pasove.
Ključne besede: ekološka regija, provenienčno območje, fitogeografska delitev, gozdni reprodukcijski material, uporaba, Slovenija
Objavljeno v DiRROS: 17.11.2020; Ogledov: 1418; Prenosov: 521
 Celotno besedilo (1,97 MB) |
125. |
126. Functional complement analysis can predict genetic testing results and long-term outcome in patients with complement deficienciesŠtefan Blazina, Maruša Debeljak, Mitja Košnik, Saša Simčič, Sanja Stopinšek, Gašper Markelj, Nataša Toplak, Peter Kopač, Breda Zakotnik, Marko Pokorn, Tadej Avčin, 2018, izvirni znanstveni članek Povzetek: Background: Prevalence of complement deficiencies (CDs) is markedly higher in Slovenian primary immunodeficiency (PID) registry in comparison to other national and international PID registries.
Objective: The purposes of our study were to confirm CD and define complete and partial CD in registered patients in Slovenia, to evaluate frequency of clinical manifestations, and to assess the risk for characteristic infections separately for subjects with complete and partial CD.
Methods: CD was confirmed with genetic analyses in patients with C2 deficiency, C8 deficiency, and hereditary angioedema or with repeated functional complement studies and measurement of complement components in other CD. Results of genetic studies (homozygous subjects vs. heterozygous carriers) and complement functional studies were analyzed to define complete (complement below the level of heterozygous carriers) and partial CD (complement above the level of homozygous patients). Presence of characteristic infections was assessed separately for complete and partial CD.
Results: Genetic analyses confirmed markedly higher prevalence of CD in Slovenian PID registry (26% of all PID) than in other national and international PID registries (0.5–6% of all PID). Complement functional studies and complement component concentrations reliably distinguished between homozygous and heterozygous CD carriers. Subjects with partial CD had higher risk for characteristic infections than previously reported.
Conclusion: Results of our study imply under-recognition of CD worldwide. Complement functional studies and complement component concentrations reliably predicted risk for characteristic infections in patients with complete or partial CD. Vaccination against encapsulated bacteria should be advocated also for subjects with partial CD and not limited to complete CD.
Ključne besede: complement deficiency, primary immunodeficiency, laboratory analysis, genetic analysis, clinical manifestations
Objavljeno v DiRROS: 12.11.2020; Ogledov: 1406; Prenosov: 602
Celotno besedilo (1000,60 KB) |
127. Predlog programa dela in finančnega načrta ZGDS za leto 2020Alojzij Gluk, Jože Falkner, Anton Lesnik, Janez Konečnik, Vasja Leban, Jože Prah, Mitja Skudnik, 2020, drugi sestavni deli Ključne besede: Zveza gozdarskih društev Slovenije, ZGDS, program dela
Objavljeno v DiRROS: 10.10.2020; Ogledov: 1579; Prenosov: 446
Celotno besedilo (64,38 KB) |
128. Poslovno poročilo Zveze gozdarskih društev Slovenije za leto 2019Alojzij Gluk, Jože Falkner, Anton Lesnik, Janez Konečnik, Vasja Leban, Jože Prah, Mitja Skudnik, 2020, drugi sestavni deli Ključne besede: Zveza gozdarskih društev Slovenije, ZGDS, poslovno poročilo
Objavljeno v DiRROS: 10.10.2020; Ogledov: 1737; Prenosov: 413
Celotno besedilo (79,65 KB) |
129. |
130. Je mogoče pripisati vrednost vsem ekosistemskim storitvam, ki jih nudi gozd?Mitja Skudnik, Polona Hafner, 2020, predgovor, uvodnik, spremna beseda Ključne besede: ekosistemske storitve, gozdovi, posredni pomen gozdov, vrednotenje
Objavljeno v DiRROS: 10.10.2020; Ogledov: 1382; Prenosov: 432
Celotno besedilo (45,36 KB) |
